

# Sodium channel blockers - Pipeline Insight, 2022

<https://marketpublishers.com/r/SE384649D104EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: SE384649D104EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Sodium Channel Blockers - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Sodium Channel Blockers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Sodium Channel Blockers Understanding

#### Sodium Channel Blockers: Overview

Sodium-channel blockers comprise the Class I antiarrhythmic compounds according to the Vaughan-Williams classification scheme. These drugs bind to and block the fast sodium channels that are responsible for the rapid depolarization (phase 0) of fast-response cardiac action potentials. This type of action potential is found in non-nodal, cardiomyocytes (e.g., atrial and ventricular myocytes; purkinje tissue). Because the slope of phase 0 depends on the activation of fast sodium-channels and the rapid entry of sodium ions into the cell (Figure: Na<sup>+</sup> in), blocking these channels decreases the slope of phase 0, which also leads to a decrease in the amplitude of the action potential.

Sodium Channel Blockers cross the blood-brain barrier and act through multiple

mechanisms. They inhibit the gamma-aminobutyric acid (GABA) system (primarily lidocaine), activate the sodium ouabain-sensitive current, stimulate 5-HT<sub>2C</sub> receptors, antagonize H<sub>1</sub> receptors and block all noradrenaline activating effect. It is through these actions that adrenergic stimulation occurs. These medications in large doses are also pro-convulsant through the above mechanisms.

Medications that act by sodium channel blockade have a wide variety of clinical applications. Broadly they include Vaughn Williams Class 1 antiarrhythmics, local anesthetics, many medications used to treat neuropathic pain (including tricyclic antidepressants (TCAs)), anticonvulsants, and cocaine. Complications of sodium channel blocker toxicity include cardiogenic shock, hypotension, bradycardia or tachycardia, cardiovascular collapse, respiratory depression, encephalopathy, status epilepticus, and death.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sodium Channel Blockers R&D. The therapies under development are focused on novel approaches for Sodium Channel Blockers.

## Sodium Channel Blockers Emerging Drugs Chapters

This segment of the Sodium Channel Blockers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Sodium Channel Blockers Emerging Drugs

### Cenobamate: SK biopharmaceuticals

Cenobamate was discovered and developed by SK Biopharmaceuticals and SK life science. It is approved for Partial epilepsies. SK Biopharmaceuticals also has an exclusive licensing agreement with Ono Pharmaceutical to develop and commercialize cenobamate in Japan.

It is currently in Phase III stage of development for Tonic-clonic epilepsy and is being developed by SK biopharmaceuticals.

BIIB095: Biogen

BIIB095 is a voltage- and use- dependent sodium channel blocker. It is a centrally and peripherally acting small molecule.

It is currently in Phase I stage of development for Neuropathic pain and is being developed by Biogen.

Further product details are provided in the report.....

Sodium Channel Blockers: Therapeutic Assessment

This segment of the report provides insights about the different Sodium Channel Blockers drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Sodium Channel Blockers

There are approx. 30+ key companies which are developing the Sodium Channel Blockers. The companies which have their Sodium Channel Blockers drug candidates in the most advanced stage, i.e. Phase III include, SK biopharmaceuticals.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Sodium Channel Blockers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Sodium Channel Blockers: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sodium Channel Blockers therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sodium Channel Blockers drugs.

### Sodium Channel Blockers Report Insights

Sodium Channel Blockers Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Sodium Channel Blockers Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Sodium Channel Blockers drugs?

How many Sodium Channel Blockers drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Sodium Channel Blockers?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sodium Channel Blockers therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Sodium Channel Blockers and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Biogen

Parion Sciences

AlphaNavi Pharma

Vertex Pharmaceuticals

SK biopharmaceuticals

UCB Biopharma

### Key Products

BIIB095

P-1037

ANP-230

VX-548

Research programme: NaV1.8 inhibitor pain therapeutics

Cenobamate

Lacosamide

## Contents

Introduction

Executive Summary

Sodium Channel Blockers: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Sodium Channel Blockers– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Sodium Channel Blockers companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Sodium Channel Blockers Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Cenobamate: SK biopharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

P-1037: Parion Sciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis



Biogen: Biogen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

Research programme: NaV1.8 inhibitor pain therapeutics: Vertex Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Sodium Channel Blockers Key Companies

Sodium Channel Blockers Key Products

Sodium Channel Blockers- Unmet Needs

Sodium Channel Blockers- Market Drivers and Barriers

Sodium Channel Blockers- Future Perspectives and Conclusion

Sodium Channel Blockers Analyst Views

Sodium Channel Blockers Key Companies

Appendix

## I would like to order

Product name: Sodium channel blockers - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/SE384649D104EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SE384649D104EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970